What is Biospectal?
Biospectal SA is a pioneering remote monitoring and biosensing software company dedicated to the global democratization of clinical monitoring. The company addresses the critical need for accessible hypertension management, a leading chronic health condition worldwide. Its flagship product, the OptiBP smartphone application and data platform, eliminates the reliance on traditional blood pressure cuffs. By enabling users to optically measure blood pressure through a fingertip placed on a smartphone camera lens, Biospectal's proprietary algorithm transforms light data into accurate blood pressure values. This innovation provides individuals with the convenience of a connected blood pressure monitor, accessible anytime and anywhere via their smartphone. Founded in July 2017, Biospectal operates from its headquarters in Lausanne, Switzerland, with an additional presence in Silicon Valley.
How much funding has Biospectal raised?
Biospectal has raised a total of $4.3M across 1 funding round:
Angel/Seed
$4.3M
Angel/Seed (2021): $4.3M with participation from Athensmed, Labcorp, Seedlink, and Privilege Ventures
Key Investors in Biospectal
Athensmed
Athensmed is an investor participating in the early-stage development of Biospectal, likely focusing on medical technology and biosensing innovations.
Labcorp
Labcorp, a prominent laboratory services company, provides vital health information and likely brings expertise in diagnostic testing and clinical data analysis to Biospectal's strategic growth.
Seedlink
Seedlink, utilizing machine learning and NLP for candidate analysis, may offer Biospectal insights into data interpretation and predictive modeling for health outcomes.
What's next for Biospectal?
With the recent major strategic investment, Biospectal is poised to accelerate its expansion and further develop its clinical monitoring platform. The enterprise-level funding suggests a transition towards scaling operations and potentially broader market penetration. Future strategic moves may involve enhancing the OptiBP application's capabilities, expanding its data analytics features, and forging partnerships within the healthcare ecosystem to integrate its technology into wider clinical workflows. This capital injection is expected to solidify Biospectal's position as a key player in the digital health sector, particularly in the management of chronic diseases like hypertension.
See full Biospectal company page
